Shield Therapeutics Plc · LSE:STX
Shield Therapeutics — Investor Presentation (October 2025)
22 slides from Shield Therapeutics's investor presentation, October 2025
Slide 1: Corporate Presentation
Corporate Presentation October 2025 Changing the Treatment Paradigm for Patients with Iron Deficiency Anemia 1
Slide 2: Disclaimer
Disclaimer These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. For the purposes of this notice, "pr
Slide 3: Shield Therapeutics
Shield Therapeutics Fast Growing, Mission Driven, Specialty Pharmaceutical Company Large global iron deficiency/iron deficiency anemia (ID/IDA) market ripe for disruption • +15 million iron deficient individuals in the US with and without anemia • 40-60% of patients on traditional irons often lead t
Slide 4: Management team
Anders Lundstrom Santosh Shanbhag Lucy Huntington-Bailey Andy Hurley David Childs Dr. Jackie Mitchell CEO CFO General Counsel Chief Commercial Officer VP, Manufacturing and VP, Quality, Clinical and Strategic Alliance Regulatory Affairs 4
Slide 5: Iron Deficiency with & without Anemia (ID/IDA)
Iron Deficiency with & without Anemia (ID/IDA) Universal problem: HCP’s are struggling to treat IDA because patients can’t tolerate the GI side effects of oral iron salts Oral ferrous salts dissociate in the stomach. Unabsorbed iron (Fe+) generates reactive oxidative species (ROS), causing irritatio
Slide 6: ACCRUFeR® designed for efficacy and tolerability
ACCRUFeR® designed for efficacy and tolerability ACCRUFeR® remains tightly bound in the stomach Unique MOA (mechanism of action) Shields and Delivers Elemental Iron to the Small Intestine 1, 2 The unique Maltol Shield protects iron from the stomach, remaining tightly bound as it passes through Propr
Slide 7: Significant window of opportunity exists for ACCRUFeR®
Significant window of opportunity exists for ACCRUFeR® Oral Iron IV Iron >90% ferrous salts2 Iron replacement that patients will actually take A well tolerated oral iron that effectively normalizes and maintains Hb, ferritin, and TSAT levels1 1. Data from AEGIS 1 and 2 study 7 2. 2023 IQVIA Xponent
Slide 8: ACCRUFeR®/FeRACCRU® (ferric maltol) portfolio – Global footprint
ACCRUFeR®/FeRACCRU® (ferric maltol) portfolio – Global footprint disease phase 1 phase 2 phase 3 regulatory marketed market opportunity Partner ID/IDA 15M Adults with ID/IDA3 (adults) co-promote 6-7% of population have ID4 Prevalence in DE: ~3.3% of ID/IDA5, UK: ~8%/3% (women/men) IDA6 decision in 2
Slide 9: While ID/IDA is vast, reaching patients who have the urgency to treat is critical
While ID/IDA is vast, reaching patients who have the urgency to treat is critical to the success of ACCRUFeR® +15 MM Adults with ID/IDA Adults with ID/IDA in the U.S. +5 MM DTC Marketing Actively Seeking Oral • ID/IDA Iron • Actively seeking oral iron treatment online 2.5 MM HCP & DTC Marketing Taki
Slide 10: Consumer related marketing efforts rapidly increasing ACCRUFeR® awareness
Consumer related marketing efforts rapidly increasing ACCRUFeR® awareness Social Media Influencers Top Social Media Channels and Digital Advertising Reached +1M patients Patient Communities Reached +3.9M patients GI side effects Fitness 9% 4% IBD 15% Nutrition & Weight Loss CKD 15% 12% Cancer 12% Be
Slide 11: Physician focused marketing efforts has expanded reach into specialists
Physician focused marketing efforts has expanded reach into specialists Sales Efforts Marketing Efforts 2025 YTD (Aug) GI, 0% Other, 3% Hem/Onc, 0% Neph, 0% GI HEM WH 10% 4% 20% NEPH 15% WH, 39% Primary care Primary Care, 22% 58% Oncology 17% Others PED 11% 1% WH = Women’s Health; HEM = Hematology;
Slide 12: Early indicators show positive impact of digital strategy on Rx
Early indicators show positive impact of digital strategy on Rx by new writers New Writer – New Rx With and Without Field Interactions New TRX w/ Field R3M New TRX w/o Field R3M 600 R3M ACCRUFeR® NRx 500 400 300 200 100 0 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 12 Internal dat
Slide 13: Key ACCRUFeR® initiatives building ACCRUFeR® momentum
Key ACCRUFeR® initiatives building ACCRUFeR® momentum Increase awareness of ACCRUFeR® • Patients and HCPs via digital marketing/initiatives • Endemic Ads and Rollout of Influencers within patient-focused social media channels • Significant increase in EMR banner marketing to providers Enhance Sales
Slide 14: #1 branded prescription oral iron in the US ID/IDA market
#1 branded prescription oral iron in the US ID/IDA* market Source: IQVIA Xponent PlanTrak *ID/IDA: Iron Deficiency with & without Anemia
Slide 15: 2025 Business Priorities
2025 Business Priorities Launch in Canada, and execute regulatory Grow ACCRUFeR® Turn Cash Flow Positive process in Korea, Net Revenues by End of 2025 China, and the Pediatric Population Q3 25 Q3 25 Q3 25 #1 branded prescription oral iron $8.6M cash and cash equivalents Priority Review by FDA for AC
Slide 16: ACCRUFeR® prescriptions demonstrating significant uptake since launch
16 - 500 1,000 1,500 2,000 2,500 3,000 3,500 4,500 5,000 4,000 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Internal data, data on file Dec-21 Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 Fully staffed Shield and May-23 Viatris sales team in t
Slide 17: ACCRUFeR® Distribution in the US
ACCRUFeR® Distribution in the US HCP and Patient discuss ACCRUFeR® HCP sends Rx to Specialty Pharmacy ACCRUFeR® ACCRUFeR® ACCRUFeR® HCP Patient Order Placed Order Placed Order Placed Prescription 3rd Party Title Model Distributor Pharmacies Logistics Provider (inventory) (inventory) (inventory) (inv
Slide 18: Continued growth in ACCRUFeR® in the US in Q3 2025
Continued growth in ACCRUFeR® in the US in Q3 2025 ACCRUFeR® Net Revenues Net Price Per Script Total Prescriptions Quarterly Quarterly Quarterly Retail Consignment c.54 $13.1M $237 $237 $231 c.47 $12.8M 12 c.44 $11.2M c.41 $187 11 c.36 c.37 43 $171 $167 16 10 37 $139 c.29 10 $7.2M $6.9M 16 31 $6.4M
Slide 19: On track to turn cash flow positive in Q4 2025
On track to turn cash flow positive in Q4 2025 driven by continued ACCRUFeR® growth in the US and effective working capital management $10 Quarterly Cash Burn (Net of New Financing) in millions Impact of one- time milestone payments $0 ($10) ($20) Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 2
Slide 20: Shield Therapeutics
Shield Therapeutics Fast Growing, Mission Driven, Specialty Pharmaceutical Company • Vast market opportunity with significant revenue potential • Shield-Viatris US partnership driving growth in ACCRUFeR® prescriptions, net revenue and net selling price • Global partnerships continue to progress at a
Slide 21: Delivering on the brand promise
Delivering on the brand promise
Slide 22: Thank You!
Thank You! Anders Lundstrom – Chief Executive Officer Santosh Shanbhag – Chief Financial Officer www.shieldtherapeutics.com 22
Shield Therapeutics — Investor Presentation (October 2025) on 6ix